Aduro BioTech, a Berkeley, CA-based biotechnology company focused on the development of therapeutic and prophylactic vaccines for infectious disease and cancer immunotherapy, announced completion of its $2m Series A-1 financing round.
Individual investors, including senior management of Aduro, provided the above mentioned capital.
Aduro’s is currently focusing on developing novel therapeutic and prophylactic vaccine technologies based on the intracellular bacterium Listeria monocytogenes, which are being designed to exploit the power of the immune system against cancer and infectious disease. According to this, the funds from the financing will be used to complete the acquisition of key intellectual property and to support late stage pre-clinical development prior to initiating clinical trials.
FinSMEs
11/11/2009